11 results about "Propionine" patented technology

This invention discloses a method for enhancing the antibacterial activity of Propionibacterium freudenreichii subsp. shermanii metabolites by adding a surfactant to a culture medium. The method uses Propionibacterium freudenreichii subsp. shermanii NBRC No. 12426 as the experimental strain and Pichia anomala SICC 2.894 as the indicator strain. A surfactant is added to the fermentation medium to enhance the antibacterial activity of the metabolites of Propionibacterium freudenreichii subsp. shermanii against the indicator strain Pichia anomala. Based on the culture conditions and method of Propionibacterium freudenreichii subsp. shermanii in this invention, the optimal concentration of the surfactant Tween-80 is selected as 0.3%, which significantly enhances the antibacterial activity of the metabolites of Propionibacterium freudenreichii subsp. shermanii.

This invention relates to fluticasone propionate cream, belonging to the field of topical pharmaceutical preparations. By using a mixed solvent of hexanediol and propylene glycol, along with a composite stabilizer, this invention solves the problem in existing fluticasone propionate creams where inappropriate intradermal retention leads to insufficient therapeutic efficacy. Simultaneously, it ensures the stability of the cream; the cream of this invention remains stable under high temperature, high temperature, light, low temperature, and freeze-thaw conditions, with no significant increase in related substances. The preparation process of the fluticasone propionate cream of this invention is simple and suitable for industrial production.

This invention discloses a pharmaceutical composition and its application, characterized by comprising tebufenozide-7-propionate (W6) and a CDK4 / 6 inhibitor. The pharmaceutical composition is used in the preparation of drugs for treating drug-resistant tumors, specifically breast cancer. Low concentrations (0.1 µM–1.0 µM) of W6 alone have no significant antitumor activity against breast cancer. However, W6 can significantly enhance the anti-breast cancer activity of CDK4 / 6 inhibitors when used in combination with them by inhibiting the drug efflux protein P-glycoprotein and regulating apoptosis and survival / proliferation signaling pathways.

The disclosure relates to pharmaceutical formulations comprising of lidocaine and halobetasol propionate, methods of making such formulations, and methods of using such formulations in the treatment of hemorrhoids.

This specification discloses a dosage form of fluticasone propionate for intra-articular administration to patients with osteoarthritis of the joints.

Provided herein are compounds and pharmaceutical compositions of formula I where R1, R2, R3, R4, R5 and R6 are as described herein. Also provided pharmaceutically acceptable salts or stereoisomers of these compounds. In addition methods are provided for inhibiting the binding of an integrin to treat various pathophysiological conditions.

This invention discloses a method and its application for enhancing the antibacterial activity of *Propionibacterium f. reudenreichii* subsp. *shermanii* metabolites by adding carrageenan to a semi-solid culture medium. The method uses *Propionibacterium f. reudenreichii* subsp. *shermanii* NBRC No. 12426 as the experimental strain and *Pichia anomala* SICC 2.894 as the indicator strain. It discloses a method for enhancing the antibacterial activity of *Propionibacterium f. reudenreichii* subsp. *shermanii* metabolites against the indicator strain *Pichia anomala* by adding carrageenan to the culture medium. Based on the culture conditions and method of *Propionibacterium f. reudenreichii* subsp. *shermanii* in this invention, the optimal amount of carrageenan added is selected as 0.6%, which significantly enhances the antibacterial activity of the *Propionibacterium f. reudenreichii* subsp. *shermanii* metabolites.

The present invention relates to the topical pharmaceutical composition comprising about 0.001% w / w to about 1% w / w latanoprost and about 1% w / w to about 15% w / w cortexolone-17α-propionate and a pharmaceutically acceptable vehicle comprising one or more solvent and process of its preparation. The invention further relates to the method wherein the composition is suitable for preventing and / or treating hair loss and / or stimulating hair growth. in patients suffering from alopecia, in particular androgenic alopecia (AGA).

The present application relates to the field of microorganisms, and provides a propionibacterium acidifaciens BL8 with functions of reducing blood sugar and resisting aging, and application thereof, the propionibacterium acidifaciens BL8 is preserved in China General Microbiological Culture Collection Center on December 20, 2024, and the preservation number is CGMCC No.33134.The propionibacterium acidifaciens BL8 of the present application can inhibit DPP4 activity, promote INS-1 insulin secretion, inhibit acetylcholinesterase activity and superior cellulase activity.Can reduce blood sugar;Improve memory, prevent and relieve Alzheimer's disease;Promote cellulose absorption, improve constipation, and have high research and application value in reducing blood sugar and resisting aging.

This invention relates to the field of antiviral drug technology, disclosing fluticasone propionate and its application in the preparation of drugs against CHIKV and EEEV. Fluticasone propionate acts on the later stages of the CHIKV and EEEV life cycle. This invention is the first to demonstrate that fluticasone propionate has significant antiviral activity against CHIKV and EEEV, filling the gap in the lack of specific treatments for these two viruses. Furthermore, the fluticasone propionate of this invention is an already marketed drug; repurposing this existing drug can significantly shorten the research and development cycle and is expected to enable rapid clinical application.

The application provides use of indole-3-propionic acid (IPA) in anti-herpes virus and a medicine and a feed additive containing the indole-3-propionic acid, and belongs to the technical field of biological medicine. The application provides application of the IPA in preparation of an antiviral agent for herpes virus, and after intervention of the IPA, the survival rate of infected mice can be obviously improved. Furthermore, after intervention of the IPA, the index of the parenchyma organs of the mice is obviously lower than that of a positive infection group; the level of inflammatory factors in each organ in the later infection stage is obviously improved, and the intestinal barrier is obviously improved; the intervention of the IPA can also obviously reduce the transcription level of PRV related genes. The IPA has the function of inhibiting pseudorabies virus replication, and can be used for preparation of a medicine for preventing and / or treating diseases caused by herpes virus infection or a corresponding feed additive.